Analysts have been eager to weigh in on the Healthcare sector with new ratings on Reata Pharmaceuticals (RETA), Arcturus Therapeutics (ARCT) and Neurocrine (NBIX).
Reata Pharmaceuticals (RETA)
In a report released yesterday, Brian Skorney from Robert W. Baird maintained a Buy rating on Reata Pharmaceuticals, with a price target of $212.00. The company’s shares closed last Monday at $126.63.
According to TipRanks.com, Skorney is a 4-star analyst with an average return of 7.1% and a 52.7% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Intellia Therapeutics, and Sarepta Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Reata Pharmaceuticals with a $212.00 average price target.
See today’s analyst top recommended stocks >>
Arcturus Therapeutics (ARCT)
Robert W. Baird analyst Michael Ulz maintained a Hold rating on Arcturus Therapeutics yesterday and set a price target of $60.00. The company’s shares closed last Monday at $54.64.
According to TipRanks.com, Ulz is a 4-star analyst with an average return of 9.6% and a 51.6% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Ultragenyx Pharmaceutical, and Alexion Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arcturus Therapeutics with a $80.80 average price target, which is a 47.9% upside from current levels. In a report issued on February 23, H.C. Wainwright also downgraded the stock to Hold with a $50.00 price target.
Neurocrine (NBIX)
In a report released today, Vamil Divan from Mizuho Securities maintained a Hold rating on Neurocrine, with a price target of $119.00. The company’s shares closed last Monday at $109.43.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -0.3% and a 45.9% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $126.45 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.